Gilead Sciences (GILD.US) acquires PepStar's oral inflammation drug project for $1.275 billion in cash, strengthening its inflammatory bowel disease pipeline.

Zhihu Finance APP has learned that Gilead Sciences (GILD.US) announced on Thursday it will acquire PepStar Therapeutics’ oral inflammation drug program for an upfront cash payment of $1.275 billion, which includes an experimental gut disease therapy. This deal comes after Gilead’s experimental oral drug emvistegrast for chronic intestinal disease reported positive mid-stage results on Monday, adding another inflammatory bowel disease (IBD) candidate to its portfolio. Gilead stated it believes HCXT-2001 has potential either as a standalone development or in combination with other pipeline projects.